Diabetes and Neurodegeneration in Wolfram Syndrome

OBJECTIVE To describe the diabetes phenotype in Wolfram syndrome compared with type 1 diabetes, to investigate the effect of glycemic control on the neurodegenerative process, and to assess the genotype-phenotype correlation. RESEARCH DESIGN AND METHODS The clinical data of 50 patients with Wolfram syndrome-related diabetes (WSD) were reviewed and compared with the data of 24,164 patients with type 1 diabetes. Patients with a mean HbA1c during childhood and adolescence of ≤7.5 and >7.5% were compared with respect to the occurrence of additional Wolfram syndrome symptoms. The wolframin (WFS1) gene was screened for mutations in 39 patients. WFS1 genotypes were examined for correlation with age at onset of diabetes. RESULTS WSD was diagnosed earlier than type 1 diabetes (5.4 ± 3.8 vs. 7.9 ± 4.2 years; P < 0.001) with a lower prevalence of ketoacidosis (7 vs. 20%; P = 0.049). Mean duration of remission in WSD was 2.3 ± 2.4 vs. 1.6 ± 2.1 in type 1 diabetes (NS). Severe hypoglycemia occurred in 37 vs. 7.9% (P < 0.001). Neurologic disease progression was faster in the WSD group with a mean HbA1c >7.5% (P = 0.031). Thirteen novel WSF1 mutations were identified. Predicted functional consequence of WFS1 mutations correlated with age at WSD onset (P = 0.028). CONCLUSIONS Endoplasmic reticulum stress–mediated decline of β-cells in WSD occurs earlier in life than autoimmune-mediated β-cell destruction in type 1 diabetes. This study establishes a role for WFS1 in determining the age at onset of diabetes in Wolfram syndrome and identifies glucose toxicity as an accelerating feature in the progression of disease.

[1]  M. Permutt,et al.  Wolfram syndrome 1 gene negatively regulates ER stress signaling in rodent and human cells. , 2010, The Journal of clinical investigation.

[2]  M. Wheeler,et al.  Differential activation of ER stress and apoptosis in response to chronically elevated free fatty acids in pancreatic beta-cells. , 2008, American journal of physiology. Endocrinology and metabolism.

[3]  P. Walter,et al.  Endoplasmic reticulum stress in disease pathogenesis. , 2008, Annual review of pathology.

[4]  D. Eizirik,et al.  The role for endoplasmic reticulum stress in diabetes mellitus. , 2008, Endocrine reviews.

[5]  R. Kaufman,et al.  Endoplasmic reticulum stress and oxidative stress: a vicious cycle or a double-edged sword? , 2007, Antioxidants & redox signaling.

[6]  V. Procaccio,et al.  Identification of novel mutations in WFS1 and genotype–phenotype correlation in Wolfram syndrome , 2007, American journal of medical genetics. Part A.

[7]  B. Vialettes,et al.  Microvascular Diabetes Complications in Wolfram Syndrome (Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy, and Deafness [DIDMOAD]) , 2007, Diabetes Care.

[8]  R. Robertson,et al.  Diabetes, glucose toxicity, and oxidative stress: A case of double jeopardy for the pancreatic islet beta cell. , 2006, Free radical biology & medicine.

[9]  M. Permutt,et al.  Mice conditionally lacking the Wolfram gene in pancreatic islet beta cells exhibit diabetes as a result of enhanced endoplasmic reticulum stress and apoptosis , 2005, Diabetologia.

[10]  F. Giuliano,et al.  Wolfram syndrome in French population: Characterization of novel mutations and polymorphisms in the WFS1 gene , 2005, Human mutation.

[11]  H. Katagiri,et al.  Disruption of the WFS1 gene in mice causes progressive beta-cell loss and impaired stimulus-secretion coupling in insulin secretion. , 2004, Human molecular genetics.

[12]  C. Cremers,et al.  Mutational spectrum of the WFS1 gene in Wolfram syndrome, nonsyndromic hearing impairment, diabetes mellitus, and psychiatric disease , 2003, Human mutation.

[13]  K. Gerbitz,et al.  Wolfram syndrome: structural and functional analyses of mutant and wild-type wolframin, the WFS1 gene product. , 2003, Human molecular genetics.

[14]  D. Ron,et al.  Endoplasmic reticulum stress and the development of diabetes: a review. , 2002, Diabetes.

[15]  G. Melino,et al.  High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program. , 2001, Diabetes.

[16]  T. Meitinger,et al.  Diabetes insipidus, diabetes mellitus, optic atrophy and deafness (DIDMOAD) caused by mutations in a novel gene (wolframin) coding for a predicted transmembrane protein. , 1998, Human molecular genetics.

[17]  D. Collier,et al.  Linkage of Wolfram syndrome to chromosome 4p16.1 and evidence for heterogeneity. , 1996, American journal of human genetics.

[18]  T. Barrett,et al.  Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome , 1995, The Lancet.

[19]  B. Kinsley,et al.  Morbidity and Mortality in the Wolfram Syndrome , 1995, Diabetes Care.

[20]  M. Swift,et al.  Psychiatric findings in Wolfram syndrome homozygotes , 1990, The Lancet.

[21]  A. Karasik,et al.  Genetically Programmed Selective Islet β-Cell Loss in Diabetic Subjects With Wolfram's Syndrome , 1989, Diabetes Care.

[22]  R. Ehrlich,et al.  Wolfram Syndrome: Report of Four New Cases and a Review of Literature , 1986, Diabetes Care.

[23]  N. Rosman,et al.  Juvenile diabetes mellitus and optic atrophy. , 1977, Archives of neurology.

[24]  C. Cremers,et al.  JUVENILE DIABETES MELLITUS, OPTIC ATROPHY, HEARING LOSS, DIABETES INSIPIDUS, ATONIA OF THE URINARY TRACT AND BLADDER, AND OTHER ABNORMALITIES (WOLFRAM SYNDROME) , 1977, Acta paediatrica Scandinavica. Supplement.

[25]  James D. Johnson,et al.  Mechanisms of pancreatic beta-cell apoptosis in diabetes and its therapies. , 2010, Advances in experimental medicine and biology.